Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurowave launches neuromodulation device for postoperative nausea

This article was originally published in Clinica

Executive Summary

Neurowave Medical Technologies has launched Reletex, a transdermal neuromodulation device designed to treat postoperative nausea, in the US. The device is worn on the wrist and generates electrical pulses that stimulate the centre of nausea control in the brain, Neurowave claims. This produces anti-nausea signals that travel from the vagus nerve to the digestive system. Reletex provides “almost immediate” relief to patients, the Chicago, Illinois-based firm said, adding that almost every patient undergoing surgery suffers from nausea. The device is cleared by the US FDA as an adjunct to anti-emetic drugs for postoperative nausea. It could reduce the need for these drugs, thereby minimising side-effects and drug interactions, Neurowave believes. The firm also markets devices for other types of nausea, including morning sickness and motion sickness.

You may also be interested in...



What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.

Topics

UsernamePublicRestriction

Register

MT095881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel